VivianWuMD

Head & Neck Microvascular Surgery, Head & Neck Oncologic Surgery

Surgeon, Otolaryngology/Head & Neck Surgical Oncology

Dr. Wu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Vivian Wu is an Otolaryngologist in Los Angeles. She specializes in Head & Neck Oncologic Surgery. Her training includes a fellowship in Head & Neck Surgical Oncology at the University of Michigan Health System and a residency in Otolaryngology - Head and Neck Surgery at Oregon Health & Science University. She has also authored several well-cited publications in the fields of surgical pathology and oncology.

University of Michigan Health SystemFellowship, Head & Neck Surgical Oncology/Microvascular Reconstruction, 2011 - 2013
Oregon Health & Science University (OHSU Health)Residency, Otolaryngology - Head and Neck Surgery, 2004 - 2011
Howard University College of MedicineClass of 2004

PubMed

Pretreatment Quality of Life and Substance Use Among Patients Diagnosed With Head and Neck Cancer.
Eric Adjei Boakye, Sami I Nassar, Suma J Alzouhayli, Amy M Williams, Steven S Chang
Cancer Medicine. 2024-11-01
Adamantinoma-Like Ewing Sarcoma Mimicking Merkel Cell Carcinoma in the Parotid Gland: A Diagnostic Pitfall.
Kasturi Saikia, Fatimah I Alruwaii, Vivian Wu, Christian Keller, Dhananjay Chitale
International Journal of Surgical Pathology. 2024-02-01
1 citations
Cognitive Function and Postoperative Outcomes in Patients with Head and Neck Cancer.
Katherine Larrabee, Nicole Meeks, Amy M Williams, Kylie Springer, Farzan Siddiqui
The Laryngoscope. 2023-11-01

Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 11th, 2020
Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin plus Nivolumab in 'Cancer Discovery' JournalMay 22nd, 2020
Hospitals Don’t Shift Costs from Medicare or Medicaid to Private InsurersJune 8th, 2017